Sanofi (SNY) Upgraded at ValuEngine

Sanofi (NYSE:SNY) was upgraded by equities research analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday.

SNY has been the subject of several other reports. Citigroup upgraded Sanofi from a “neutral” rating to a “buy” rating in a research note on Friday, August 10th. Zacks Investment Research raised Sanofi from a “sell” rating to a “hold” rating in a report on Tuesday, July 3rd. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a report on Monday. Deutsche Bank reaffirmed a “buy” rating on shares of Sanofi in a report on Wednesday, August 1st. Finally, Bank of America raised Sanofi from a “neutral” rating to a “buy” rating and set a $55.00 target price on the stock in a report on Monday, September 10th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the company. The company has an average rating of “Hold” and an average target price of $49.00.

Shares of NYSE:SNY traded up $0.33 during trading on Wednesday, hitting $44.68. The stock had a trading volume of 975,700 shares, compared to its average volume of 1,882,403. Sanofi has a 12-month low of $37.43 and a 12-month high of $50.04. The stock has a market cap of $112.04 billion, a price-to-earnings ratio of 14.27, a PEG ratio of 2.40 and a beta of 0.82. The company has a quick ratio of 0.85, a current ratio of 1.22 and a debt-to-equity ratio of 0.40.

Sanofi (NYSE:SNY) last announced its quarterly earnings data on Tuesday, July 31st. The company reported $0.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.02. Sanofi had a return on equity of 23.77% and a net margin of 10.29%. The firm had revenue of $8.18 billion during the quarter, compared to analysts’ expectations of $8.27 billion. During the same period last year, the business posted $1.35 earnings per share. The company’s revenue for the quarter was down 5.6% compared to the same quarter last year. As a group, equities analysts anticipate that Sanofi will post 3.14 EPS for the current fiscal year.

In related news, major shareholder Sanofi sold 104,552 shares of the firm’s stock in a transaction dated Thursday, September 6th. The stock was sold at an average price of $406.68, for a total transaction of $42,519,207.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.00% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently modified their holdings of the business. Institute for Wealth Management LLC. grew its holdings in Sanofi by 27.4% in the second quarter. Institute for Wealth Management LLC. now owns 31,936 shares of the company’s stock valued at $1,278,000 after purchasing an additional 6,860 shares during the period. Van ECK Associates Corp grew its holdings in Sanofi by 15.1% in the second quarter. Van ECK Associates Corp now owns 361,195 shares of the company’s stock valued at $14,451,000 after purchasing an additional 47,420 shares during the period. Signaturefd LLC grew its holdings in Sanofi by 32.0% in the second quarter. Signaturefd LLC now owns 10,266 shares of the company’s stock valued at $411,000 after purchasing an additional 2,486 shares during the period. Providence Capital Advisors LLC grew its holdings in Sanofi by 46.0% in the second quarter. Providence Capital Advisors LLC now owns 30,016 shares of the company’s stock valued at $1,201,000 after purchasing an additional 9,460 shares during the period. Finally, Nomura Holdings Inc. grew its holdings in Sanofi by 51.8% in the second quarter. Nomura Holdings Inc. now owns 50,726 shares of the company’s stock valued at $2,030,000 after purchasing an additional 17,310 shares during the period. 7.54% of the stock is currently owned by institutional investors.

About Sanofi

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an oral immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

See Also: Price to Earnings Ratio (PE) Basics

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply